{"id":46894,"date":"2025-11-12T16:32:46","date_gmt":"2025-11-12T08:32:46","guid":{"rendered":"https:\/\/flcube.com\/?p=46894"},"modified":"2025-11-12T16:32:46","modified_gmt":"2025-11-12T08:32:46","slug":"ankebio-and-persongen-ink-capital%e2%80%91increase-deal-secure-exclusive-greater%e2%80%91china-agency-for-pa3%e2%80%9117-car%e2%80%91t-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46894","title":{"rendered":"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy"},"content":{"rendered":"\n<p><strong>Anhui Anke Biotechnology (Group) Co., Ltd.<\/strong> and <strong>PersonGen BioTherapeutics (Suzhou) Co., Ltd.<\/strong> (PersonGen) announced today a <strong>dual\u2011track strategic partnership<\/strong> that combines a <strong>RMB\u202f30\u202fmillion capital injection<\/strong> with an <strong>exclusive agency agreement<\/strong> for PersonGen\u2019s lead product, <strong>PA3\u201117 injection<\/strong>, across the <strong>Greater China<\/strong> region (Mainland, Hong\u202fKong, Macau, Taiwan).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Capital increase<\/strong><\/td><td>AnkeBio, now the <strong>second\u2011largest shareholder<\/strong>, will invest <strong>RMB\u202f30\u202fmillion<\/strong> in PersonGen, deepening its equity stake.<\/td><\/tr><tr><td><strong>Exclusive agency rights<\/strong><\/td><td>AnkeBio obtains sole commercialisation rights for <strong>PA3\u201117 injection<\/strong> in Greater China.<\/td><\/tr><tr><td><strong>Strategic shift<\/strong><\/td><td>Moves from early\u2011stage R&amp;D collaboration to a <strong>\u201ccapital\u2011binding + joint\u2011commercial\u2011operation\u201d<\/strong> model.<\/td><\/tr><tr><td><strong>Timeline<\/strong><\/td><td>Investment and agency agreement effective <strong>Q4\u202f2025<\/strong>; commercial launch targeted <strong>2027<\/strong> pending Phase\u202f2 read\u2011out.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-spotlight-pa3-17-injection\">Product Spotlight \u2013 PA3\u201117 Injection<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic class:<\/strong> Autologous <strong>CAR\u2011T<\/strong> cell therapy targeting <strong>CD7<\/strong>.<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First IND\u2011approved CD7 CAR\u2011T that <strong>avoids gene editing<\/strong>, eliminating fratricide and tumour\u2011cell contamination while employing a proprietary quality\u2011control platform.<\/li>\n\n\n\n<li><strong>Clinical data:<\/strong> Phase\u202f1 trial showed <strong>favourable safety<\/strong> and <strong>high complete\u2011response rates<\/strong> in relapsed\/refractory <strong>T\u2011ALL<\/strong> and <strong>T\u2011LBL<\/strong> patients.<\/li>\n\n\n\n<li><strong>Regulatory status:<\/strong> Granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> by the NMPA\u2019s Center for Drug Evaluation (CDE) and now advancing in a <strong>pivotal Phase\u202f2<\/strong> study.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>T\u2011ALL\/T\u2011LBL unmet need:<\/strong> Approximately <strong>2,500<\/strong> new paediatric and adult T\u2011cell acute leukaemia cases are diagnosed annually in China, with a <strong>relapse rate >\u202f30\u202f%<\/strong> after standard chemotherapy.<\/li>\n\n\n\n<li><strong>Pricing potential:<\/strong> Early market modelling suggests a <strong>treatment price of \u00a51.5\u2013\u00a52.0\u202fmillion<\/strong> per course, comparable to imported CAR\u2011T products but with a domestic supply\u2011chain advantage.<\/li>\n\n\n\n<li><strong>Revenue outlook:<\/strong> Assuming a <strong>5\u202f% market capture<\/strong> of the relapsed\/refractory T\u2011cell leukaemia segment, AnkeBio could generate <strong>\u00a53\u2013\u00a55\u202fbillion<\/strong> in net sales by 2030.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Capital\u2011backed commercialisation:<\/strong> The RMB\u202f30\u202fmillion infusion provides PersonGen with the cash runway to accelerate Phase\u202f2 enrolment and manufacturing scale\u2011up.<\/li>\n\n\n\n<li><strong>AnkeBio\u2019s commercial muscle:<\/strong> Leveraging its established sales network and regulatory expertise, AnkeBio can fast\u2011track market entry across the Greater China region.<\/li>\n\n\n\n<li><strong>Pipeline synergies:<\/strong> The partnership creates a platform for future <strong>CAR\u2011T<\/strong> collaborations, potentially expanding into other CD\u2011targeted programmes.<\/li>\n<\/ol>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the capital increase, commercial launch timeline, pricing, and market potential for PA3\u201117. Actual results may differ due to clinical outcomes, regulatory review, competitive dynamics, and execution of the partnership.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46896,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[482,1752],"class_list":["post-46894","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-anke-biotechnology","tag-persongen-biotherapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today a dual\u2011track strategic partnership that combines a RMB\u202f30\u202fmillion capital injection with an exclusive agency agreement for PersonGen\u2019s lead product, PA3\u201117 injection, across the Greater China region (Mainland, Hong\u202fKong, Macau, Taiwan).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46894\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy\" \/>\n<meta property=\"og:description\" content=\"Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today a dual\u2011track strategic partnership that combines a RMB\u202f30\u202fmillion capital injection with an exclusive agency agreement for PersonGen\u2019s lead product, PA3\u201117 injection, across the Greater China region (Mainland, Hong\u202fKong, Macau, Taiwan).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46894\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T08:32:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1207.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46894#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46894\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy\",\"datePublished\":\"2025-11-12T08:32:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46894\"},\"wordCount\":402,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46894#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1207.webp\",\"keywords\":[\"Anke Biotechnology\",\"PersonGen BioTherapeutics\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46894#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46894\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46894\",\"name\":\"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46894#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46894#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1207.webp\",\"datePublished\":\"2025-11-12T08:32:46+00:00\",\"description\":\"Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today a dual\u2011track strategic partnership that combines a RMB\u202f30\u202fmillion capital injection with an exclusive agency agreement for PersonGen\u2019s lead product, PA3\u201117 injection, across the Greater China region (Mainland, Hong\u202fKong, Macau, Taiwan).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46894#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46894\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46894#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1207.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1207.webp\",\"width\":1080,\"height\":608,\"caption\":\"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46894#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today a dual\u2011track strategic partnership that combines a RMB\u202f30\u202fmillion capital injection with an exclusive agency agreement for PersonGen\u2019s lead product, PA3\u201117 injection, across the Greater China region (Mainland, Hong\u202fKong, Macau, Taiwan).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46894","og_locale":"en_US","og_type":"article","og_title":"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy","og_description":"Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today a dual\u2011track strategic partnership that combines a RMB\u202f30\u202fmillion capital injection with an exclusive agency agreement for PersonGen\u2019s lead product, PA3\u201117 injection, across the Greater China region (Mainland, Hong\u202fKong, Macau, Taiwan).","og_url":"https:\/\/flcube.com\/?p=46894","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-12T08:32:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1207.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46894#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46894"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy","datePublished":"2025-11-12T08:32:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46894"},"wordCount":402,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46894#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1207.webp","keywords":["Anke Biotechnology","PersonGen BioTherapeutics"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46894#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46894","url":"https:\/\/flcube.com\/?p=46894","name":"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46894#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46894#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1207.webp","datePublished":"2025-11-12T08:32:46+00:00","description":"Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today a dual\u2011track strategic partnership that combines a RMB\u202f30\u202fmillion capital injection with an exclusive agency agreement for PersonGen\u2019s lead product, PA3\u201117 injection, across the Greater China region (Mainland, Hong\u202fKong, Macau, Taiwan).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46894#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46894"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46894#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1207.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1207.webp","width":1080,"height":608,"caption":"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46894#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AnkeBio and PersonGen Ink Capital\u2011Increase Deal, Secure Exclusive Greater\u2011China Agency for PA3\u201117 CAR\u2011T Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1207.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46894"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46894\/revisions"}],"predecessor-version":[{"id":46897,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46894\/revisions\/46897"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46896"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}